Beta Bionics experiences a rise in sales, while Dexcom announces the recruitment of a new Chief Creative Officer
In the rapidly evolving landscape of diabetes technology, two major players, Dexcom and Beta Bionics, are making significant strides.
Dexcom, a leader in continuous glucose monitoring (CGM) devices, has appointed Jon Coleman as its new chief commercial officer (CCO). This strategic move is likely aimed at bolstering commercial growth, market penetration, and competitive positioning in the diabetes technology space [1][2].
Meanwhile, Beta Bionics, known for its automated insulin delivery systems, has experienced remarkable growth. The company went public in January, raising $204 million in an upsized initial public offering. In the first quarter of this year, Beta Bionics reported a 145% increase in sales to $20.4 million, with the expansion into the pharmacy market being a key contributor [1][2].
Beta Bionics' expansion into the pharmacy market, marked by the addition of its iLet Bionic Pancreas to Prime Therapeutics' largest national commercial formulary in February 2025, significantly broadens its market access. This strategic move aims to increase patient uptake through easier and more widespread insurance coverage and accessibility via pharmacy benefit plans (PBP) rather than solely through durable medical equipment (DME) channels [1][2].
Dexcom's latest CGM, the G7, is 4.7mm thick and weighs 3.3g, while Beta Bionics' GS3, claimed to be the world's thinnest CGM, is 2.9mm thick and weighs 1.5g. Sibionics, another player in the market, offers the SiWatch, a watch that connects to its CGM, allowing users to view glucose data on their wrists. Sibionics' CGM utilizes artificial intelligence to help users better understand glucose data [1].
Sibionics' GS3 uses near field communication to pair with other devices, and it recently received a CE mark for the GS3 continuous glucose monitor. Notably, Sibionics became the first company to receive approval for a fingerstick-free CGM in China in 2021 [1].
The increase in sales at Beta Bionics was driven by nearly 4,100 new patient starts. Leerink analysts cited "better-than-expected pharmacy adoption" as a positive for the company. The pharmacy channel is expected to account for more than 20% of new patient starts this year for Beta Bionics [1].
Dexcom's revenue forecast was lowered last year amid a restructuring of its salesforce, but the workers it has brought in have "now become more productive," according to CEO Kevin Sayer. Sales were 2% above the consensus estimate of Wall Street analysts, Leerink Partners [1].
These developments imply a maturing diabetes technology market with companies like Beta Bionics focused on expanding access through pharmacy channels, which can lower barriers for users, while industry leaders like Dexcom are reinforcing their commercial leadership to defend and grow their positions.
The implications for the diabetes technology industry include greater patient access and convenience, increased competition and innovation, enhanced commercial strategies, and potential shifts in reimbursement landscapes [1][2]. This evolution towards greater integration of advanced delivery systems, digital health tools, and simplified access pathways could significantly improve diabetes management outcomes and market growth dynamics.
References: [1] Beta Bionics' Expansion into Pharmacy Market (2025). Retrieved from www.betabionics.com/news [2] Dexcom Appoints Jon Coleman as Chief Commercial Officer (2025). Retrieved from www.dexcom.com/news
- The diabetes technology market is experiencing significant advancements, with companies like Dexcom and Beta Bionics making considerable strides.
- Dexcom, a prominent medtech player, recently appointed Jon Coleman as its new CCO to boost commercial growth and market position.
- Beta Bionics, famous for its AI-powered automated insulin delivery systems, raised $204 million through an initial public offering and reported a 145% increase in sales this year.
- To increase patient uptake, Beta Bionics expanded into the pharmacy market, securing broader market access and easier insurance coverage.
- Sibionics, another medtech firm, introduced the world's thinnest CGM device and the SiWatch, a gadget that connects to its CGM, allowing users to view glucose data on their wrists.
- The pharmacy channel is expected to account for over 20% of new patient starts this year for Beta Bionics, following "better-than-expected pharmacy adoption."
- Dexcom's revenue forecast was revised down last year but has since bounced back due to heightened productivity in the restructured salesforce.
- This evolution in diabetes technology may lead to improved diabetes management outcomes, increased innovation, and potential reimbursement landscape shifts, thanks to advancements in analytics, data-and-cloud-computing, and wearables.
